Update Review and Clinical Presentation in Congenital Insensitivity to Pain and Anhidrosis by Pérez-López, L. M. et al.
Case Report
Update Review and Clinical Presentation in Congenital
Insensitivity to Pain and Anhidrosis
L. M. Pérez-López,1 M. Cabrera-González,1 D. Gutiérrez-de la Iglesia,1
S. Ricart,2 and G. Knörr-Giménez1
1Pediatric Orthopaedic Surgery Department, Sant Joan de Déu Children’s Hospital, University of Barcelona, Barcelona, Spain
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Copyright © 2015 L. M. Pérez-López et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Introduction. Congenital insensitivity to pain and anhidrosis (CIPA) or hereditary sensory and autonomic neuropathy type IV is
an extremely rare syndrome. Three clinical findings define the syndrome: insensitivity to pain, impossibility to sweat, and mental
retardation.This pathology is caused by a genetic mutation in the NTRK1 gene, which encodes a tyrosine receptor (TrkA) for nerve
growth factor (NGF).Methods. The consultation of a child female in our center with CIPA and a tibia fracture in pseudoarthrosis
encouraged us to carefully review literature and examine the therapeutic possibilities. A thorough review of literature published
in Pubmed was done about CIPA and other connected medical issues mentioned in the paper. Conclusions. The therapeutic
approach of CIPA remains unclear. The preventive approach remains the only possible treatment of CIPA. We propose two new
important concepts in the therapeutic approach for these patients: (1) early surgical treatment for long bone fractures to prevent
pseudoarthrosis and to allow early weight bearing, decreasing the risk of further osteopenia, and (2) bisphosphonates to avoid the
progression of osteopenia and to reduce the number of consecutive fractures.
1. Introduction
Congenital insensitivity to pain and anhidrosis (CIPA), also
known as hereditary sensory and autonomic neuropathy type
IV, is an extremely rare syndrome. The first reference to a
similar pathology was mentioned by Dearborn in the early
1900s [1], and it was published in 1963 by Swanson [2]. Three
clinical findings define the syndrome: insensitivity to pain,
inability to sweat, and mental retardation [3, 4]. Only a few
hundreds of cases of CIPA have been recently published
worldwide [5, 6]. This condition occurs with an incidence of
1 in 125 million newborns [7].
The pathogenesis of CIPA is characterized by a genetic
loss-of-function mutation of the NTKR1 gene (locus 1q 21-
22) [8, 9]. Multiple new mutations have been progressively
described [10–16]. NTRK1 mutations imply an alteration
in TrkA, a NGF receptor. NGF is involved in surveillance
of nociceptive sensory neurons and sympathetic autonomic
neurons and collaborates in the activation and homeostasis
of other cellular types so that a NTRK1 mutation will cause
deficient development of [17–20]
(1) the afferent somatic sensory system for pain and tem-
perature, located in the dorsal root ganglion sensory
neurons,
(2) the autonomic sympathetic neuronal system, which
implies loss of the innervation of eccrine sweat glands
by sympathetic neurons,
(3) the central nervous system,
(4) the bidirectional communication between the im-
mune system and the nervous system (NGF has a
relevant role in the signal pathway of B lymphocytes
through three processes: Trk A phosphorylation,
cytoskeleton assemblage, and MAP kinase activa-
tion).
The molecular alteration in the function of NGF in turn
also alters the normal process of fracture consolidation [21].
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Normal osteoblast/osteoprogenitor differentiation and pro-
liferation are hindered, tending to result in fibroblast dif-
ferentiation of multipotent stromal mesenchymal cells and
periosteal cells.
Bone metabolism is also affected by the lack of noci-
ceptive fibers, present not only in the skin but also in the
skeletal system [22]. Due to the trophic role that nociceptive
fibers may play in the skeletal system, bone fractures are very
common [23].
2. Case Presentation
Medical record and radiographic data of the present casewere
reviewed and reported in a study approved by the department
of documentation of our hospital. The patient’s parents also
gave their consent. A thorough review of the PubMed litera-
ture on CIPA and associated medical conditions mentioned
in this paper was performed (Table 1). This case report is an
illustrative example of a patient affected by CIPA.
We present a case involving a seven-year-old, female child
of Spanish nationality. She had been evaluated in another
center for episodes of recurrent fever. After a long diagnostic
process including a pertinent genetic study which detected
two mutations in the NTRK1 gene responsible for CIPA,
she was diagnosed with the syndrome [8]. Her parents were
healthy, and no consanguinity was present.
Clinical exploration revealed absence of a pain response,
recurrent episodes of fever, sweating deregulation, mental
retardation, cutaneous autolesions, fracture without consol-
idation, avascular necrosis (Figure 1), demineralized bones,
generalized osseous destruction (Figure 2), warm and dry
skin with thickening of the soles and palms, and lower limb
edema (Figures 3(a), 3(b), and 3(c)) [5, 24–26].
The patient was referred to our center four months after
fracture of themiddle shaft of the right tibia. Radiologic signs
of hypertrophic pseudoarthrosis were present (Figure 4). An
elastic intramedullary nailing was carried out [27]. Complete
radiological consolidation of the fracture was achieved five
months after the surgery (Figure 5).
In the following months, several fractures occurred,
including a fifthmetatarsal fracture in the right foot (Figure 1)
and a fourth metatarsal fracture in the left foot, a right
femoral middle shaft fracture that was surgically treated with
good results (Figures 6(a), 6(b), and 6(c)), and an epiphys-
iolysis at the distal shaft of the right tibia. In CIPA, due to
the alteration of the bone fracture metabolism, hypertrophic
bone callus (Figures 1, 4, and 6(c)) and pseudoarthrosis
(Figure 4) are very common. In the present patient, bone
consolidation was only achieved when a surgical technique
was applied.
During this period of time with recurrent fractures,
treatment with bisphosphonates was started. A dose of
1mg/Kg/day during 3 consecutive days of intravenous
pamidronate was administered every four months, for one
year. We obtained good results in preventing new fractures
at upper and lower limbs, skull, and spine bones at 5
years of follow-up. No adverse effects were seen regarding
pamidronate infusion or during the follow-up.
At 5 years of follow-up, patient has progressed.
Figure 1: Navicular avascular necrosis and fifth metatarsal fracture
in the right foot with hypertrophic bone callus.
Figure 2: Demineralized bones and generalized osseous destruc-
tion.
3. Discussion
CIPA is an autosomal recessive disorder [8]. Some cases of
consanguinity have been described among affected patients
[7, 28]. Apart from the already well-defined genetic transmis-
sion of CIPA, there is an infrequent non-Mendelian inher-
itance characterized by uniparental disomy of chromosome
1 [10]. It is described by the transmission of an autosomal
recessive pathology fromonly one affected parent.Themolec-
ular genetic analysis of the presented patient detected two
heterozygous mutations in the NTRK1 gene (c.2205+1G>T
in intron 16 and c.360-45C>A in intron 3), found also in her
mother, suggesting then uniparental disomy.
The therapeutic approach to CIPA is still evolving and
remains controversial [7]. There is no definitive agreement
regarding its management, and therapeutic options are
restricted to treatment of symptoms and protection from self-
mutilation, fractures, and wound infections, which may lead
to amputation. Such limited treatment options imply poten-
tially catastrophic consequences of the natural pathologic
evolution of the disease. Fractures associated with CIPA may
be devastating and deeply affect the patient’s functionality.
Surgical treatment provides stability to the focal point of
the fracture, helping to provide definitive consolidation.
Moreover, immobilization contributes to accelerated bone
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Table 1: Thorough review of the PubMed literature on CIPA and associated medical conditions mentioned in this paper was performed.
References Year of publication Particularity of the observation and remarks for each reading
Dearborn [1] 1932 First reference, in literature, to a similar disease
Swanson [2] 1963 First reference, in literature, to CIPA
Nishida [3] 1951 Three clinical representative findings: insensitivity to pain,
inability to sweat, and mental retardationTunçbilek et al. [4] 2005
Rosemberg et al. [5]
review
1994 Only 32 cases have been published worldwide




2012 Incidence 1 in 125 million newborns
Indo et al. [8] 1996 CIPA pathogenesis: genetic loss-of-function mutation of
Indo et al. [9] 1997 the NTKR1 gene (locus 1q 21-22). NTKR1 mutations
imply an alteration in TrKA, A NGF receptor
Indo et al. [8] 1996 Autosomal recessive disorder
Indo [10] 2001
Not only autosomal recessive inheritance, but also
uniparental disomy (non-Mendelian inheritance of
autosomal recessive disease from a single carrier parent, as
the exposed case)
Indo [10] review 2001
Novel mutation and polymorphism in the NTRK1 gene
causing CIPA
Indo et al. [15] 2001
Bonkowsky et al. [11] 2003
Lin et al. [12] 2010
Mardy et al. [16] 2001
Miura et al. [13] 2000
Weier et al. [14] 1995
Bonkowsky et al. [11] 2003
Indo [25] review 2002 A very profuse resume of clinical and genetic characteristicsof CIPA
Indo [18] 2010 NGF receptor failure causes a deficient development of dorsal
root neurons (pain and temperature sensory system)
autonomic sympathetic neural system (eccrine sweat glands
innervation)
Central nervous system
The signal pathway of B lymphocytes
Indo [19] 2012
Tanaka et al. [20] 1990




Melamed et al. [21] 2004
Grills and Schuijers [24] 1998 NGF function disruption also causes an altered process offracture consolidation
Fruchtman et al.[26] 2013 Descriptive clinical presentation including morbidity
Yang et al. [27] 2013 conditions (some of these clinical facts are also present in thecase reported)
Jarade et al. [35] review 2002 Ocular manifestations
Brandes and Stuth [39] 2006 Anaesthetic considerations
Oliveira et al. [40] 2009
Abdulla et al. [33] 2014 Heterotopic ossification and callus formation followingfractures, eventually Charcot’s joint
Schreiber et al. [41] 2005 Insulin-related difficulties
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Figure 3: Lower limb edema.
Figure 4: Hypertrophic bone callus.
demineralization. Surgical fracture repair allows for early
weight bearing, diminishing the risk of further osteopenia,
which is also usually present in these patients as a part of their
associated neurogenic arthropathy (Figure 3) [21].
Figure 5: Complete radiological consolidation of the tibia fracture
was achieved five months after the surgery.
For all of these reasons, we recommend early surgical
treatment of fractures. It allows for more rapid functional
recovery, reducing the risk of accelerated osteopenia due to
immobilization.
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Figure 6: Right femoral middle shaft fracture that was surgically treated with good results. Hypertrophic bone callus associated.
The use of bisphosphonates in patients affected by CIPA
had never been mentioned before in literature. Due to
our previous good experience with pamidronate in treating
osteoporotic fractures for disuse in children with different
medical conditions [29, 30], we made a therapeutic approach
with pamidronate as a compassionate use in this child. We
obtained good results in preventing new fractures.
These two therapeutic observations might be relevant in
the absence of specific treatment for CIPA. However, we may
not forget that further studies addressing CIPA management
are needed to provide more rigorous and scientific conclu-
sions.
CIPA may present various signs and symptoms that can
be misleading. The differential diagnoses of this pathology
include radicular hereditary sensory neuropathy (HSN I);
hereditary sensory and autonomic neuropathy (HSN II);
familial dysautonomia or Riley-Day syndrome (HSN III)
[31]; congenital indifference to pain (HSN V) [32]; and
Lesch-Nyhan syndrome. Corneal ulcers are also relatively
frequent in patients with CIPA. A differential diagnosis of
neurotrophic keratitis may be taken into consideration [33,
34]. Among all these diagnostic possibilities and according
to Raspall-Chaure [29],
CIPAmust be the first diagnostic hypothesis when assess-
ing a patient with insensitivity to pain, anhidrosis, and self-
mutilation.
According to literature, the first step in the diagnosis of
CIPA syndrome is consideration of the clinical presentation
based on the combination of three basic signs: insensitivity to
pain, anhidrosis, andmental retardation [3, 4]. Other possible
signs may be associated: impaired temperature sensation
[5], facial alterations [6], mandibular osteolysis [7], dental
caries [6], and premature tooth loss [6]; repetitive soft
tissue and osseous infections of hematogenous origin [33],
mainly caused by S. aureus [25]; self-mutilating behavior [7];
occasional microcephaly [5, 24]; urine and fecal incontinence
[11]; growth disturbances; and heterotopic ossification [7, 35,
36].
Neurological laboratory tests may provide additional
information. Short-latency somatosensory evoked potentials
show marked prolongation of the central conduction time
[19] and microneurography reveals abnormal activity of
somatic A-delta and C fibers in the nerves of the skin [6, 37,
38]. A negative sympathetic skin responsemay also be helpful
in the diagnosis due to the lack of sudomotor nerves in skin
biopsy [38].
Pharmacologic tests that evaluate autonomic function are
also useful. The Mecholyl test produces prompt pupillary
miosis [24], pain test results abnormal [6, 13, 24], there is
an absence of a flare reaction to the histamine test [24]
(although we may find some normal responses to subdermal
histamine injection) [11], and the sweat test using pilocarpine
reveals a disruption of sweat gland function. Histopathologic
evaluation shows a hyperplastic epidermis with acanthosis
and hyperkeratosis and a decreased amount of sweat and
sebaceous glands [6].
Finally,molecular evaluation that revealsmutations of the
NTKR1 gene provides a definitive diagnosis [19, 24].
About the anesthetic considerations [39, 40], although
pain stimuli are absent, anxiety associated with surgical pro-
cedures may generate stress and consequent hemodynamic
instability. It is necessary tominimize preoperative apprehen-
sion and anxiety with the use of sedatives. Also the autonomic
response to surgery is inconsistent and erratic, which results
in difficulty determining the necessary anesthetic doses in
advance. Finally, temperature control is crucial. Malignant
hyperthermia or hypothermia may be lethal.
NGF-TrkA pathway has a role in the morphogenesis of
the endocrine pancreas, in insulin secretion in vitro, and in
insulin secretion in response to glucose. Patients with CIPA
present with alterations of the first phase of insulin secretion
[41].
The similarities between CIPA and reflex sympathetic
dystrophy are very interesting. Both are characterized by
neurogenic inflammation, skin alterations with vasomotor
disruption, and osteopenia.
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Some authors have focused on establishing a specific
treatment for complex regional pain syndrome by studying
the role of receptor tyrosine kinase for NGF in patients with
CIPA [29].
The high incidence of infections in patients with CIPA
is also problematic. Skin and deep bone infections are the
most common types, and Staphylococcus aureus is the most
commonly involved pathogen.
Resistance to antibiotics is a frequently occurring limita-
tion in the treatment of these patients [25].
Temperature deregulation may cause recurrent fever,
which may lead to death if not recognized early.
Other complications such as trauma or soft tissue/bone
infection may decrease condition of the survival rate,
although all are treatable conditions if diagnosed in a timely
manner [7].
The best therapeutic approach to patients with CIPA
appears to be based on prophylactic measures such as braces
for early weight bearing in nonsurgical fractures and accurate
follow-up to avoid missing complications. We propose an
unusual treatment challenge, with an early surgical treatment
for long bone fractures and early use of bisphosphonates as
follows.
Therapeutic proposals are as follows:
(1) Surgical fracture repair to achieve an early functional
recovery that avoids a final destructive situation.
(2) Bisphosphonates use to manage osteoporosis.
Addressing the cause of CIPA as opposed to solely symp-
tomatic treatment seems to be the optimal therapeutic
approach. If CIPA results from loss-of-function mutations in
the NTRK1 gene encoding TrkA, then molecular treatment
involving a receptor tyrosine kinase for NGF would be the
most effective therapeutic technique.
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